Delivery Order SPE2DB20D2104-SPE2DB23FS42T
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Cencora, Inc. The $1,612.53 firm fixed-price delivery order is for the supply of XULANE 150-35 MCG/DAY PATCH 3S, a contraceptive patch, with a period of performance through January 4, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,355.75 firm fixed-price delivery order is for the pharmaceutical product Xulane 150-35 mcg/day patch, a contraceptive medication. The contract has an ultimate completion date of May 22, 2023 and is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999...
- This federal contract award, valued at $3,162.43, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Xulane 150-35 mcg/day patch, a contraceptive product, and is classified as a Firm Fixed Price Delivery Order. The contract has an ultimate completion date of April 11, 2025 and is not set aside for any specific business category. Amerisourcebergen Drug Corp holds...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,238.60 firm fixed-price contract is for the provision of XULANE 150-35 MCG/DAY PATCH 3S, a contraceptive patch. The contract has an ultimate completion date of August 13, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This federal contract award, valued at $5,916.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Xulane 150-35 mcg/day contraceptive patches, a pharmaceutical product. The contract has a completion date of January 25, 2023 and is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has been awarded multiple...
- This federal contract award, with a ceiling value of $1,127.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of Xulane 150-35 mcg/day contraceptive patches. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization that is registered in the System for Award Management (SAM.gov) through June 2025. The contract has no set-aside...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) for the supply of XULANE 150-35 MCG/DAY PATCH 3S, a transdermal contraceptive patch. The contract has a ceiling value of $32,587.35 and an ultimate completion date of March 13, 2025. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,657.38 firm fixed-price delivery order is for the supply of XULANE 150-35 MCG/DAY PATCH 3S, a transdermal contraceptive patch. The contract has an ultimate completion date of September 13, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,401.85, is a delivery order for the supply of Xulane 150-35 mcg/day patch, a hormonal contraceptive product. The contract is a firm fixed-price arrangement with an ultimate completion date of April 29, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,922.69 firm fixed-price delivery order is for the supply of XULANE 150-35 MCG/DAY PATCH 3S, a contraceptive medication. The contract has an ultimate completion date of December 14, 2022 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FS42TDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Xulane 150-35 mcg/day Patch 3s, a prescription contraceptive patch. The contract has a ceiling value of $2,033.04 and a completion date of March 2, 2023. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 3/1/23 |